“I thought there was no hope once the cancer spread to my brain—but I didn’t even need surgery, and after just a few sessions, the tumor had shrunk!”

65-year-old Mr. Li, a lung cancer patient, smiled again after completing his CyberKnife treatment.

 A few months ago, Mr. Li was diagnosed with brain metastasis from lung cancer—a 2 cm lesion in his right parietal lobe. Faced with the high risks of craniotomy and the potential memory loss from whole-brain radiotherapy, he was understandably anxious. Fortunately, his doctors recommended CyberKnife radiosurgery.

His entire treatment took just 3 sessions, each lasting under 40 minutes. Apart from mild scalp tightness, he experienced almost no discomfort. A follow-up MRI one month later showed a clear reduction in tumor size, with his neurological functions fully preserved—his memory and mobility remained intact.

 Today, with the advancement of precision radiosurgery, CyberKnife is bringing new hope to many patients with brain metastases.

01. Brain Metastases: No Longer a “Dead End”

In the past, hearing that a tumor had spread to the brain almost meant a countdown to the end of life. Brain metastases are among the most common complications in advanced cancers, occurring 8–10 times more frequently than primary brain tumors.

Patients often suffer from headaches, nausea, limb weakness, or seizures—symptoms that not only impair daily life but can also become life-threatening.

 However, medical progress has turned despair into hope. Technologies such as stereotactic radiosurgery (SRS), represented by the CyberKnife system, now make precise control of brain metastases possible.

 Studies have shown that in patients with single brain metastases, CyberKnife treatment can extend median survival from 3–6 months to over one year. Even for patients with multiple lesions, combining CyberKnife with systemic therapies can significantly delay disease progression and improve quality of life.

02. CyberKnife: The “Invisible Scalpel” of Precision and Gentleness

The CyberKnife is not an actual knife—it’s a robotic, AI-guided, high-precision radiosurgery system.

Driven by a robotic arm, the linear accelerator delivers high-energy beams from hundreds of angles, converging precisely on the tumor target. Its targeting accuracy reaches the sub-millimeter level—up to 0.1 mm.

Unlike conventional radiotherapy, CyberKnife features real-time image tracking. Even if the patient moves slightly or breathes during treatment, the system automatically adjusts the radiation beam to stay locked on the tumor, sparing surrounding healthy brain tissue.

 Treatment typically involves 1–5 sessions, each lasting about 15–30 minutes. It’s non-invasive, painless, and requires no anesthesia. Patients can go home immediately after each session without hospitalization.

03. Fractionated Treatment: High Efficiency with Brain Protection

One of CyberKnife’s most notable advantages in treating brain metastases is fractionated radiosurgery—delivering radiation in multiple smaller doses.

This strategy allows enough energy to kill tumor cells effectively while giving surrounding healthy brain tissue time to recover, achieving a balance between efficacy and safety.

 High precision and efficacy: CyberKnife can focus high-dose radiation on millimeter-sized lesions, even those near critical structures like the brainstem or optic nerve. Studies report local control rates of 70–90% for brain metastases.

Cognitive preservation: Unlike whole-brain radiotherapy, CyberKnife targets only tumor tissue, minimizing widespread radiation injury and greatly reducing cognitive side effects such as memory loss or attention deficits.

Personalized planning: For larger or functionally sensitive lesions, doctors can apply a multi-session high-dose approach, gradually shrinking the tumor while maintaining safety.

Safe for critical areas: CyberKnife shows outstanding results for brainstem metastases, achieving a 94% one-year local control rate with very low complication risk.

With its precision, gentleness, and repeatability, CyberKnife has become a new direction in the management of intracranial metastases.

04. Who Benefits Most from CyberKnife?

Although CyberKnife is powerful, it’s not suitable for everyone. Generally, the best candidates include:

1. Patients with 1–4 lesions, each smaller than 3–4 cm in diameter.

2. Lesions located near functional or critical brain areas, where surgery poses high risk.

3. Patients in poor general condition, unable to tolerate surgery, or wishing to avoid whole-brain radiotherapy.

4. Those with multiple small metastases, where CyberKnife can be combined with systemic therapy for effective control.

5. Patients with larger lesions, where staged or fractionated treatment can first reduce tumor size and then deliver a second round for optimal results.

Whether CyberKnife is appropriate must be determined by an experienced radiosurgery team through multidisciplinary evaluation and individualized treatment planning.

05. Treatment Process and Follow-Up Care

CyberKnife treatment generally involves three key stages: localization, planning, and delivery.

Before treatment: Doctors use MRI or CT scans to determine the exact tumor position and size, creating a 3D image model to design a personalized radiation plan.

During treatment: The patient lies comfortably on the treatment couch—no anesthesia or rigid head frame is needed. The robotic arm moves flexibly around the head, delivering beams from hundreds of angles for complete coverage.

After treatment: Patients can leave the treatment room immediately. Most experience only mild fatigue or scalp tightness, which usually resolves quickly.

Follow-up enhanced MRI scans are recommended to assess treatment response and detect new lesions.

If necessary, short-term steroid medication may be prescribed to reduce brain edema.

06. Conclusion

In the past, brain metastases were often viewed as the “final chapter” of cancer treatment.

Today, CyberKnife—with its precision, gentleness, and repeatability—is opening a new chapter of survival.

It represents not just a technological breakthrough, but also a shift in philosophy—

from simply treating disease to preserving brain function,

from extending life to improving its quality.

With the continued advancement of AI-guided imaging and multidisciplinary collaboration, CyberKnife is set to play an even greater role in the management of brain metastases—

helping more patients, like Mr. Li, rediscover dignity, confidence, and the joy of life through science and hope.